Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | LTK | P29376 | 1/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431582 | 0.85 | NOTUM (0.56) | NOTUMTRPV1CHEK1AURKADAPK3 | |
| SCHEMBL4437276 | 0.84 | EPHX2 (0.48) | NOTUMTRPV1EPHX2PPARDPPARA | |
| SCHEMBL5451262 | 0.84 | EPHX2 (0.48) | NOTUMTRPV1EPHX2PPARDPPARA | |
| SCHEMBL2107054 | 0.83 | NOTUM (0.62) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL2431070 | 0.81 | NOTUM (0.70) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL28946942 | 0.81 | SIRT2 (0.48) | NOTUMTRPV1EPHX2PPARDPPARA | |
| SCHEMBL31124025 | 0.80 | NOTUM (0.71) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL1686268 | 0.79 | KIF11 (0.54) | NOTUMTRPV1CHEK1AURKADAPK3 | |
| SCHEMBL23863307 | 0.78 | NOTUM (0.70) | NOTUMCHEK1AURKADAPK3JAK2 | |
| SCHEMBL14069278 | 0.78 | NOTUM (0.70) | NOTUMCHEK1AURKADAPK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417334-A | Azole derivative containing isoxazole structure, and preparation method and application thereof | 沈阳药科大学 | 2024-01-19 | — | — | CN | disclosed |
| US-8633184-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-01-21 | — | — | US | disclosed |
| US-8633184-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-01-21 | — | — | US | disclosed |
| EP-2010289-B1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-30 | — | — | EP | disclosed |
| US-7781469-B2 | Arylacetate derivatives having isoxazole skeleton | SHIONOGI & CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781469-B2 | Arylacetate derivatives having isoxazole skeleton | SHIONOGI & CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781469-B2 | Arylacetate derivatives having isoxazole skeleton | SHIONOGI & CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7678786-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-16 | — | — | US | disclosed |
| WO-2004091604-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | BRATTON LARRY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040176383-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004067506-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1406898-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030181352-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030176447-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003008411-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181352-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | NOTUM 725/4885TRPV1 548/4885CHEK1 3918/4885 |
| US-20030176447-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | NOTUM 725/4885TRPV1 548/4885CHEK1 3918/4885 |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | NOTUM 2730/4885TRPV1 391/4885CHEK1 3411/4885 |
| US-20040176383-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | NOTUM 725/4885TRPV1 548/4885CHEK1 3918/4885 |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARG, PPARD | NOTUM 534/4885TRPV1 733/4885CHEK1 4053/4885 |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | NOTUM 1370/4885TRPV1 365/4885CHEK1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.